Drug intelligence / Profile preview

XKZ2305 granules

Development stage
Phase 2
Lead developer
Nanjing University of Chinese Medicine
Administration
Oral
01

Overview

XKZ2305 granules (XKZ2305颗粒) is a Class 1.1 innovative Traditional Chinese Medicine (TCM) granule formulation developed by Liancheng Xunkang in collaboration with Nanjing University of Chinese Medicine and Jiangsu Province Hospital of Chinese Medicine. It is derived from the hospital's internal preparation 'Xiao'er Jiangqi Pingxiao Heji' (小儿降气平哮合剂), which is based on the classic TCM formulas 'San'ao Decoction' (三拗汤) and 'Sanzi Yangqin Decoction' (三子养亲汤). XKZ2305 granules are designed to treat pediatric bronchial asthma during acute exacerbations characterized by the 'external cold and internal heat' syndrome (儿童哮喘急性发作期,外寒内热证). The formulation works by relieving bronchospasm, easing asthma, suppressing cough, resolving phlegm, promoting diaphoresis, and clearing internal heat. It is currently in Phase II clinical development in China.

Other names
Xiao'er Jiangqi Pingxiao HejiXiao'er Jiangqi Pingxiao MixtureXKZ2305颗粒小儿降气平哮合剂
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)BCL-2 (BCL-2 family)GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)HIF1A (Hypoxia-inducible factor 1-alpha)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on XKZ2305 granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on XKZ2305 granules.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call